Skip to content

Medicinal Chemistry

CSIR NET Chemical Sciences medicinal chemistry: drug targets and inhibition, logP and QSAR, metabolism and pharmacokinetics, and the major therapeutic classes.

4
Topics
63
Min read

Chapter Overview

Medicinal Chemistry appears in the CSIR NET Chemical Sciences syllabus as a single line under the interdisciplinary topics: Medicinal chemistry. There are no official sub-topics, which means the examiner can ask anything that a chemist would recognise as the chemistry of drug molecules — and in practice the questions sit at the junctions this unit covers: physical organic chemistry applied to binding and inhibition, structure–activity reasoning, the organic chemistry of metabolism, and the mechanisms of the major therapeutic classes.

That makes it an unusually rewarding unit, because almost nothing in it is new. Michaelis–Menten kinetics come from Chemical Kinetics, Hammett constants from Reaction Mechanisms, partition from Analytical Chemistry, haem chemistry from Bioinorganic Chemistry, and the ring systems from Heterocyclic Compounds. Medicinal chemistry is where they are used together.

What You’ll Learn

By the end of this chapter you will be able to:

  • Identify the target class of a drug and describe how it is engaged — reversible, covalent or mechanism-based inhibition, agonism or antagonism
  • Convert between \( K_d \), \( K_i \), IC\(_{50}\) and \( \Delta G^\circ \), apply the Cheng–Prusoff relations, and read a Schild plot
  • Compute \( \log D \) from \( \log P \) and \( pK_a \), count Lipinski violations, and reason about why lipophilicity has an optimum
  • Set up and interpret a Hansch or Free–Wilson QSAR, find the optimum \( \log P \), and judge whether a fit is trustworthy
  • Predict the likely sites of phase I and phase II metabolism, recognise bioactivation, and explain prodrug and soft-drug design
  • Carry out standard pharmacokinetic calculations: \( t_{1/2} \), \( V_d \), clearance, AUC, bioavailability, loading dose and time to steady state
  • State the target and structural logic of the major antibacterial, antiviral, anticancer, anti-inflammatory, cardiovascular and CNS classes

Prerequisites


Learning Path

graph TD
    A["1. Drug Targets and Drug Action
enzymes, receptors, channels, DNA;
Ki, IC50, Schild, covalent inhibition"] --> B["2. Properties, SAR and QSAR
logP and logD, pKa, Lipinski,
pharmacophore, bioisosteres, Hansch"] B --> C["3. Metabolism, Prodrugs and PK
phase I and II, P450, prodrugs,
half-life, clearance, bioavailability"] C --> D["4. Major Drug Classes
antibacterial, antiviral, anticancer,
NSAID, cardiovascular, CNS"] A --> D D --> E["Quick Revision
one-page sheet"] C --> E

Topics in This Chapter

#TopicWhat it covers
1Drug Targets and Molecular Basis of Drug ActionEnzymes, receptors, ion channels and nucleic acids as targets; \( K_d \), \( K_i \), IC\(_{50}\), EC\(_{50}\) and \( \Delta G^\circ \); Cheng–Prusoff; competitive, uncompetitive and allosteric inhibition; transition-state analogues; covalent and mechanism-based inhibitors; agonists, partial agonists and antagonists; Schild analysis; selective toxicity and the therapeutic index
2Physicochemical Properties, SAR and QSAR\( \log P \), \( \pi \) and \( \log D \); \( pK_a \), ionisation and the pH–partition idea; Lipinski and Veber rules; SAR tactics; pharmacophores; classical and non-classical bioisosterism; the Hansch equation and optimum \( \log P \); Craig plots, Topliss tree, Free–Wilson and 3D-QSAR; ligand efficiency and LLE
3Drug Metabolism, Prodrugs and PharmacokineticsADME; phase I oxidation by cytochrome P450 and non-P450 routes; phase II conjugations and their cofactors; bioactivation and reactive metabolites; blocking metabolism; prodrugs and soft drugs; chirality in drug action; \( t_{1/2} \), \( V_d \), clearance, AUC, bioavailability, loading dose, steady state and saturated elimination
4Major Drug Classes and Their Chemistryβ-Lactams and resistance; glycopeptides; ribosome-targeting antibiotics; quinolones; the folate pathway; antivirals and antifungals; alkylating agents, antimetabolites and antimitotics; NSAIDs and opioids; cardiovascular, gastrointestinal and CNS classes; heterocycles in drug design
—Quick RevisionEvery formula, target and trap from the chapter on one page

Where each official syllabus line is covered

Official topic linePage
Medicinal chemistry1 (targets, binding and inhibition, receptor pharmacology); 2 (physicochemical properties, SAR, QSAR, drug-likeness); 3 (metabolism, prodrugs, pharmacokinetics); 4 (therapeutic classes and their structural chemistry)

The official syllabus lists this unit as a one-line interdisciplinary topic with no sub-topics; the four pages above divide it on textbook lines, not official ones.


How CSIR NET Asks It

Chemical Sciences is marked as follows, per the NTA information bulletin for the December 2026 cycle (one paper, 3 hours, 200 marks):

PartQuestions givenAttemptCorrectWrongMaximum
B4035+2−0.570
C6025+4−1100

If more than the permitted number are answered in a part, only the first ones up to that number are evaluated. The bulletin gives no count of questions per syllabus line. The kinds of question this chapter supports:

  • Part B: the target of a named drug or class; the type of inhibition shown by a kinetic description; the meaning of IC\(_{50}\) versus \( K_i \); \( \log D \) from \( \log P \) and \( pK_a \); counting Lipinski violations; identifying a phase I versus a phase II transformation; naming what a prodrug releases; a one-step half-life, clearance or bioavailability calculation; recognising a bioisosteric replacement.
  • Part C: extracting \( K_i \) from IC\(_{50}\) with \( [\mathrm{S}] \) and \( K_M \) given; reading a Schild experiment; diagnosing covalent versus tight-binding reversible inhibition from time- and dialysis-dependence; predicting activity from a Hansch equation and a table of \( \sigma \) and \( \pi \); ranking leads by ligand efficiency; full concentration–time data worked through to \( V_d \), CL and AUC; and “which of the following statements are correct” sets on resistance mechanisms, metabolic liabilities or class SAR.

Quick Reference

ConceptKey fact
Binding free energy\( \Delta G^\circ = RT\ln K_d \); one log unit ≈ 5.7 kJ mol⁻¹ at 298 K
Cheng–Prusoff\( K_i = \mathrm{IC}_{50}/(1 + [\mathrm{S}]/K_M) \)
Schild\( r - 1 = [\mathrm{B}]/K_B \), slope 1; p\(A_2 = -\log K_B \)
Distribution\( \log D = \log P - \log(1 + 10^{\Delta}) \); \( \Delta = \mathrm{pH} - \mathrm{p}K_a \) (acid), \( \mathrm{p}K_a - \mathrm{pH} \) (base)
Lipinskimass ≤ 500, \( \log P \) ≤ 5, donors ≤ 5, acceptors ≤ 10
Hansch\( \log(1/C) = -k_1(\log P)^2 + k_2\log P + k_3\sigma + \cdots \); \( \log P_0 = k_2/(2k_1) \)
Efficiency\( \mathrm{LE} \approx 1.37\,\mathrm{pIC}_{50}/N_{\text{heavy}} \); \( \mathrm{LLE} = \mathrm{pIC}_{50} - \log P \)
Metabolismphase I functionalises (P450 monooxygenase), phase II conjugates (UDPGA, PAPS, GSH, acetyl-CoA, SAM)
Pharmacokinetics\( t_{1/2} = 0.693/k \); \( \mathrm{CL} = kV_d \); \( \mathrm{AUC} = FD/\mathrm{CL} \); steady state in 4–5 half-lives
Selectivityabsent target, different target, different activation, different subtype

Metal-based drugs, imaging agents and chelation therapy are treated in Metal Complexes in Medicine, and the enzyme kinetics behind inhibition in Chemical Kinetics. For the subject overview and marking, see Chemical Sciences.


Start Learning

→ Drug Targets and Molecular Basis of Drug Action

Advertisement
Advertisement